Table 3 Multiple linear regression evaluating factors associated with final BVA at 3 and 5 years.

From: Evaluating the long-term predictive value of macular thickness fluctuations on diabetic macular oedema response to anti-VEGF treatment

 

3-year

5-year

Coefficients

Estimate

SD

P-value

Estimate

SD

P-value

Intercept

10.46

32.40

0.7492

29.37

23.15

0.2016

CST SD

−0.06

0.05

0.2791

−0.09

0.05

0.1093

Baseline CST

−0.007

0.02

0.7707

0.02

0.02

0.3346

CAT SD

0.02

0.05

0.7423

−0.06

0.09

0.5016

Baseline CAT

−0.01

0.02

0.5454

0.002

0.03

0.9454

CV SD

1.01

1.80

0.5759

−0.06

0.09

0.5016

Baseline CV

−0.49

0.61

0.4199

0.002

0.03

0.9454

CST AUC

0.001

0.005

0.8147

0.005

0.005

0.9916

CST Amplitude

−0.04

0.03

0.2584

−0.06

0.05

0.2204

Baseline ETDRS

0.46

0.02

0.0001**

0.23

0.19

0.00003***

Age

0.03

0.28

0.9078

0.11

0.19

0.5638

Male

7.80

6.01

0.1997

0.78

4.04

0.8468

Other Race

8.11

5.34

0.1309

−3.02

7.83

0.7007

White

4.35

2.95

0.1429

0.42

4.64

0.9285

Left Eye

3.55

2.45

0.1485

1.604

4.004

0.6894

PDR

0.49

2.84

0.8633

−1.98

4.59

0.6667

Insulin Use

0.65

2.89

0.8171

−3.13

4.66

0.5024

Total anti-VEGF injections

0.77

0.51

0.1317

1.74

0.82

0.0865

  1. **≤0.01; ***≤0.001
  2. Statistical significance is denoted by p < 0.05 and bolded (multiple linear regression).
Back to article page